243641-77-2Relevant academic research and scientific papers
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin αvβ3) antagonists
Miller, William H.,Manley, Peter J.,Cousins, Russell D.,Erhard, Karl F.,Heerding, Dirk A.,Kwon, Chet,Ross, Stephen T.,Samanen, James M.,Takata, Dennis T.,Uzinskas, Irene N.,Yuan, Catherine C. K.,Haltiwanger, R. Curtis,Gress, Catherine J.,Lark, Michael W.,Hwang, Shing-Mei,James, Ian E.,Rieman, David J.,Willette, Robert N.,Yue, Tian-Li,Azzarano, Leonard M.,Salyers, Kevin L.,Smith, Brian R.,Ward, Keith W.,Johanson, Kyung O.,Huffman, William F.
, p. 1483 - 1486 (2007/10/03)
In our continuing efforts to identify small molecule vitronectin receptor antagonists, we have discovered a series of phenylbutyrate derivatives, exemplified by 16, which have good potency and excellent oral bioavailability (approximately 100% in rats). T
Vitronectin Receptor Antagonists
-
, (2008/06/13)
Compounds of the formula (1) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis:
